Alpha Crest Capital Management LLC Travere Therapeutics, Inc. Transaction History

Alpha Crest Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$22.91 - $28.63 $32,875 - $41,084	1,435 Added 13.45%	12,107 $298,000
Q2 2022 Aug 11, 2022	SELL	$20.94 - $30.01 $204,814 - $293,527	-9,781 Reduced 47.82%	10,672 $259,000
Q1 2022 May 12, 2022	SELL	$23.61 - $30.6 $834,330 - $1.08 Million	-35,338 Reduced 63.34%	20,453 $527,000
Q4 2021 Feb 09, 2022	BUY	$24.34 - $31.17 $1.36 Million - $1.74 Million	55,791 New	55,791 $1.73 Million
Q3 2021 Nov 10, 2021	SELL	$12.98 - $25.03 $641,212 - $1.24 Million	-49,400 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$14.11 - $26.4 $697,034 - $1.3 Million	49,400 New	49,400 $721,000

198

84.9M

776K

912K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.3B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Crest Capital Management LLC with notifications on news.